VACC: Controversial anti-dengue program is worse than any heinous crime | Inquirer News

VACC: Controversial anti-dengue program is worse than any heinous crime

/ 12:49 PM December 02, 2017

Volunteers Against Crime and Corruption founding chair Dante Jimenez. INQUIRER FILE PHOTO

A group of anticorruption advocates appealed to the Department of Justice (DOJ) to launch an investigation into the government’s dengue immunization program that has potentially exposed children to a more serious health risk.

The Volunteers Against Crime and Corruption (VACC) said on Saturday that they would file a request to urge the DOJ to mobilize the National Bureau of Investigation in looking into the health issue.


On Wednesday, pharmaceutical giant Sanofi Pasteur disclosed that children who have not yet been afflicted with dengue and have received the vaccine Dengvaxia are exposed to “more cases of severe disease.”

READ: Pharma firm issues caution on use of anti-dengue vaccine


The Department of Health (DOH) immediately ordered the suspension of the P3.5-billion vaccination program, which rolled out in 2016.

Dante Jimenez, VACC chair, noted in a press briefing in Quezon City that they would also appeal to Health Secretary Francisco Duque III to set up “centers” in provinces where parents whose children have received Dengvaxia may file their complaints.

“This is even worse than any heinous crimes,” Jimenez said.

Those responsible for the procurement of the vaccine should be held accountable, the group said, adding that those affected may also file class suits for damages. /jpv


Citing risks, DOH stops P3.5-B dengue vaccine drive

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: dengue, Dengvaxia, DoH, DoJ, NBI, Sanofi, VACC, vaccine
For feedback, complaints, or inquiries, contact us.

News that matters

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

© Copyright 1997-2021 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.